Next Science Limited

As of December 31, 2024, Next Science Limited has 292.16M shares outstanding.

These figures are as of December 31, 2024. The price-to-sales ratio is 0.91, and the price-to-book ratio stands at 0.46.

These figures are as of December 31, 2024. The EV/Sales ratio of 0.95 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Next Science Limited trades at an EV/FCF ratio of 24.73, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of December 31, 2024, Next Science Limited maintains a current ratio of 1.88, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 72.42, indicating elevated leverage, while an interest coverage ratio of -40.85 demonstrates limited ability to service its debt obligations.

Over the twelve months ended December 31, 2024, Next Science Limited posted a negative return on equity (ROE) of -21.14, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -78.08, reflecting losses generated across the asset base. Inventory turnover of 6.04 indicates how many times Next Science Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2024, Next Science Limited posted a gross margin of 80.83, reflecting its pricing power and cost economics. The operating margin of -50.84 and net profit margin of -46.40 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2024. Free cash flow yield stands at 2.84, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -8.43, meaning Next Science Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of December 31, 2024, Next Science Limited has an Altman Z-Score of -16.95, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.